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The extracellular-signal-regulated-kinase (ERK) signaling pathway is essential for vertebrate development and is frequently
deregulated in human and zebrafish tumors. Previously, we cloned and characterized the zebrafish MAPK gene family and
showed that ERK2 is crucial for cell migration and early zebrafish embryogenesis. To further study ERK2 function we
generated constitutively active mutant forms of the ERK proteins by introducing conserved point mutations. We validated the
enhanced protein activity in vitro by transfection of constructs into zebrafish fibroblast (zf4) cells and demonstrated elevated
phosphorylation levels of downstream targets P90RSK and CREB, by ERK2L84P/S162D and ERK2L84P/S162D/D330N specifically. In vivo
validation was performed by ectopic expression of corresponding mRNAs in the transgenic zebrafish FGF-ERK2 reporter fish
line Tg(Dusp6:d2EGFP). Both mutant ERK2 isoforms induced elevated transgene expression compared to ERK2WT, confirming
increased kinase activity in vivo. Phospho-kinomic analysis on peptide microarrays was performed to identify new targets in
embryos injected with FGF8 or ERK2L84P/S162D/D330N mRNAs. We detected both FGF8 specific and common signalling targets.
Interestingly, with both mRNAs we found increased phosphorylation levels of CDK1, which is critical for proper G2/M phase
transition and mitotic entry in proliferation control. These results corroborate that constitutive activation of the ERK2 pathway
leads to enhanced, possibly oncogenic, proliferation.
1. Introduction
The mitogen-activated protein (MAP) kinases extracellular
signal-regulated kinases 1 and 2 (ERK1 and ERK2) are
crucial components of the regulatory machinery underly-
ing normal and malignant cell proliferation. The rat sar-
coma (RAS)/rapidly accelerated fibrosarcoma (RAF)/MAPK
kinase (MEK1/2)/ERK1/2 oncogenic pathway is induced by
various growth factors and forms a convergence point of
multiple signaling pathways to control essential cellular
processes including migration, differentiation, growth, and
survival [1–5]. Approximately, 30% of all human cancers dis-
play evidence of enhanced activation of the RAS/RAF/MEK
MAPK pathway [6]. This pathway has been extensively
studied in relation to tumor formation and this was greatly
facilitated by the availability of constitutively active forms of
RAS, RAF, and MEK [7, 8]. Expression of oncogenic RAS
as well as constitutive active forms of RAF, and MEK can
lead to induced tumorigenic transformation of NIH 3T3 cells
[9, 10]. In addition, in vivo studies with transgenic mice
models, expressing constitutive active MEK in the heart, lens
chondrocytes, or skin, displayed increased cell numbers or
cell size and a delayed onset of cell differentiation [11].
Melanoma is a form of cancer with an extremely high
frequency of deregulated RAF/MEK/ERK as 70% of the
melanoma cases harbour increasing activity mutations in
the RAF oncogene [12]. The activating mutation in B-RAF
(BRAFV600E) found in humannevi drives generation of nevi
in zebrafish when expressed in melanocytes. Coupled with
the loss of the tumor-suppressor gene P53, nevi progress from
benign clusters of melanocytes to malignant melanoma [13,
14].This indicates that pathology andmolecular mechanisms
of tumor formation between humans and zebrafish are sim-
ilar. In addition, providing molecular tools for establishing
zebrafish cancer models proved to be valuable for a better
understanding of pathogenesis [15–19].
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Table 1: Primer list for site-directed mutagenesis.
Description Sequence (5󸀠 > 3󸀠) Reference
MAPK1/ERK2
ERK2/L84P fw CTGCGTGAGATTAAAATCCCGCTCCGCTTCAAGC
RefSeq: NM 182888
ERK2/L84P rv GCTTGAAGCGGAGCGGGATTTTAATCTCACGCAG
ERK2/S162D fw CGAGACCTGAAGCCAGACAACCTGTTGCTCAACAC
ERK2/S162D rv GTGTTGAGCAACAGGTTGTCTGGCTTCAGGTCTCG
ERK2/D330N fw CCTGGAGCAGTACTATGATCCTACAAATGAGCCTGTTGCTGAG
ERK2/D330N rv CTCAGCAACAGGCTCATTTGTAGGATCATAGTACTGCTCCAGG
MAPK3/ERK1
ERK1/L106P fw CTGAGAGAGATCAAAATCCCCCTGCGGTTCCATC
RefSeq: NM 201507
ERK1/L106P rv GATGGAACCGCAGGGGGATTTTGATCTCTCTCAG
ERK1/S184D fw CAGAGACCTGAAGCCCGACAACCTTCTCATCAACAC
ERK1/S184D rv GTGTTGATGAGAAGGTTGTCGGGCTTCAGGTCTCTG
ERK1/D352N fw GCAGTACTATGACCCATCTAATGAGCCGGTAGCTGAGGAAC
ERK1/D352N rv GTTCCTCAGCTACCGGCTCATTAGATGGGTCATAGTACTGC
The same signaling pathways that orchestrate embryonic
development are frequently deregulated during tumor pro-
gression. In fact, these signaling pathways appear to add
significantly to the aggressiveness of tumors. Proteins critical
in embryogenesis can be reactivated in adult cells and play
a role in allowing tumor cells to overcome barriers and to
metastasize [20–22]. Recent studies in our laboratory have
demonstrated that depletion of ERK2 in zebrafish disturbs
cell migration mechanisms and causes developmental arrest
in an early embryonic (blastula) stage. Although the apparent
ERK1/2 gene expression levels appear to be constant during
all stages of early zebrafish development, differences in
ERK1/2 signal activity is first detected with whole mount
immunohistochemistry in the enveloping layer (EVL) of the
early blastula [23]. During epiboly ERK1/2 activity is induced
at the margin by fibroblast growth factor (FGF) morphogens
and controls convergent extension cellmovements andmeso-
derm differentiation [23].
We expect that overactivation of ERK2 will increase the
proliferation andmigration properties of cells in the develop-
ing embryo, leading to aberrant developmental program and
perhaps tumor formation. In this study, we aim to focus on
the ERK/MAPK level of the oncogenic RAS/RAF/MEK/ERK
cascade by constructing zebrafish constitutive active mutants
that are independent of negative feedback signaling. These
tools will be used to understand the downstream molecular
mechanisms that are involved in developmental processes,
which also play a role in converting normal to uncontrolled
cell proliferation. The results illustrate that zebrafish is a
powerful vertebrate model that allows simultaneous study
of embryonic development and tumor progression using
multidisciplinary approaches.
2. Material and Methods
2.1. Site-Directed Mutagenesis. The amino acid substitutions
were generated in zERK1 and zERK2 by site-directedmutage-
nesis using the QuikChange(R) site-directed mutagenesis kit
(Stratagene). Primers (Sigma-Aldrich) were designed accord-
ing to the guidelines of the supplied protocol and used for the
mutagenesis reaction (Table 1). A forward and reverse primer
is designed for each mutation. The primers (forward and
reverse) overlap themutation and haveminimal 10 residues at
each side of the mutation.The nucleotides complementary to
themutation site are changed to generate the desired substitu-
tions.The four reaction steps of the site-directedmutagenesis
kit were performed with 10 ng PCS2+zERK1 or PCS2+zERK2
DNA.Double and triplemutants were generated by repeating
the four steps of the mutagenesis reaction with the single and
double mutant DNA templates, respectively. The Leucine to
Proline substitution was generated by replacing CTC with
a CCC codon in ERK1 and CTG with CCG in ERK2, the
Serine to Aspartic acid substitution by replacing the TCA
with GAC in both ERK1 and ERK2. Finally, the Aspartic
acid to Asparagine substitution was obtained by GAT to
AAT replacement in zERK1 and zERK2. Importantly, no
residues other than the one of interest were found mutated.
Sequencing analysis confirmed the successful introduction of
all mutations. Importantly, no other residues than the one of
interest were found mutated.
2.2. Transfection of PCS2+ERK1/2 (mut) in zf4 Cells. The
transfection experiments were performed with the FuGene
HD transfection reagent (Roche). A transfection mix con-
taining 1.5 𝜇g construct DNA, the FuGene reagents, and plain
medium (without FCS) was applied to a confluent layer of
cells in 0.5mL medium and incubated for 6 h. To allow
the cells to recover 1.0mL medium with FCS was added
for overnight incubation. PCS2+ERK1 and PCS2+ERK2
(mutated) constructs were transfected in zf4 cells and after
recovery starved for 6.5 hours. The protein was isolated
directly after starvation in 1X SDS sample buffer (RedLoading
Buffer Pack 1723 Cell Signaling Technology).
2.3. mRNA Synthesis. The PCS2+ERK2 WT PCS2+ERK2∗
PCS2+ERK2∗∗ and PCS2+ERK2∗∗∗ constructs were lin-
earized with Apa1 prior mRNA synthesis with the mMes-
sage mMachine kit (Ambion). 1𝜇g of the purified digest
was used for the mRNA synthesis reaction with Sp6 RNA
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Table 2: MAPK activating mutations.
Organism Gene name Activating mutations Reference
Rat rERK2/MAPK1 L73P S151D D319N Emrick et al. 2001 [24]
Yeast FUS3 L63P D317N Hall et al. 1996 [25]
Drosophila rolled (rl) D334N Brunner et al. 1994 [26]
Zebrafish zMAPK3/ERK1 L106P
∗ S184D∗∗ D352N∗∗∗
zMAPK1/ERK2 L84P∗ S162D∗∗ D330N∗∗∗
∗Single mutant, containing L to P substitution.
∗∗Double mutant, containing L to P and S to D substitutions.
∗∗∗Triple mutants, containing L to P and S to D and D to N substitutions.
polymerase. Subsequently, 1𝜇l of DNAse was added to the
reaction which is incubated for 30min at 37∘C. The mRNA
samples were purified with the NucleoSpin RNA Clean-up
kit (Nucleobond) and analysed by electrophoresis on a 1%
RNAse-free agarose gel.
2.4. Microinjection in Zebrafish Embryos. 1.0 nL ERK
(mutant) mRNA (50 ng/𝜇l) was injected into one-cell stage
Tg(Dusp6:d2EGFP) zebrafish embryos. Injected embryos
were used for protein isolation at 5 hours after fertilization
(hpf), imaged with LEICA MZ12, or analyzed with COPAS
XL from Union Biometrica.
2.5. Protein Isolation from Zebrafish Embryos. Injected
embryos of 5 hpf were mechanically dechorionated and kept
until protein isolation in agarose coated wells filled with
1X Danieau buffer. For isolation embryos were disrupted in
Ca2+/Mg2+ free solution and cells were subsequently washed
with PBS. 1 𝜇L/embryos of 1X lysis buffer (1M Tris-Hcl pH7.4,
0.5M EDTA, 1 tablet protease inhibitor, 0.1M Na
3
VO
4
, 0.5M
NaF) was added. 2 ug protein from zebrafish embryos was
used for western blotting.
2.6. Western Blotting. Protein samples were loaded on a
10% acrylamide PAGE gel. The high range rainbow molec-
ular weight marker (RPN756 V, Amersham Biosciences)
was used for band size determination. After blotting on
a nitrocellulose membrane, the blot was incubated with
1 : 1000 diluted Phospho-p90RSK Thr573 (9346), Phospho-
p44/42 MAP Kinase Thr202/Tyr204 (9101), p44/42 MAP
Kinase (9102), Phospho-Elk-1 Ser383 (9181), Phospho-CREB
Ser133 (9198), and phospho-p90RSK Ser380 (9341) rabbit
antibody (Cell Signaling technology). The ECL western
blotting detection reagents and analysis system (Amersham
Biosciences) was used for chemoluminescence detectionwith
secondary antibody, the ECL-HRP Linked Anti-rabbit IgG
(Amersham).Theblotswere strippedwithWestern-Re-Probe
Reagent (G-Biosciences) for restaining.
2.7. Serine Threonine Kinome Profiling. Protein samples were
prepared as described previously except that M-PER lysis
buffer with phosphatase and protease inhibitors (PIERCE)
was used. Samples were snapfreezed in liquid nitrogen and
delivered to PamGene International BV for analysis. 1 𝜇g
of each lysate was loaded on PamChip arrays, with 144
immobilized peptide substrates in a porous ceramic mem-
brane, and incubated in the presence of 400 𝜇L ATP. Func-
tional readout is based on kinetic measurement of Ser/Thr
phosphorylation occurring on the array using fluorescently
labelled anti-phospho-antibodies. Data processing including
image quantification, quality control, statistical analysis, and
visualization was performed using the Bionavigator software.
3. Results
3.1. Conserved Constitutive Activating Mutation Sites in ERK2
Orthologues over Different Evolutionary Phyla. Previous
large-scale mutation screens of the Drosophila melanogaster
gene rolled and Saccharomyces cerevisiae gene fus3 have
facilitated the construction of the constitutive active rat
orthologue ERK2 [24]. Three point mutations (L73P, S151D,
and D319N) were found to increase the kinase activity a
100-fold compared to the wild-type rERK2 when introduced
simultaneously. In addition, Emrick et al. demonstrates, with
an in vitro test were the rates of phosphoryl transfer from
[−32P] ATP to myelin basic protein were measured in 10min
assays, that the L73P/S151D ERK2 double mutant was 50-fold
more active.Themutations enhance ERK2 activitymost likely
by facilitating intramolecular autophosphorylation predom-
inantly at Tyr-185 and to a lesser extent at Thr-183. As in the
wild type, phosphorylation at both sites is required for full
activation of ERK2 [24]. Considering the high conservation
of MAPKs in vertebrates, these point mutations could pos-
sibly activate the zebrafish orthologue of rat ERK2 and since
ERK1 and ERK2 are 90% identical the same mutations may
also activate zERK1. Multiple alignment including the amino
acid sequence of FUS3, ROLLED, rat ERK2, and zebrafish
ERK1 and ERK2 showed an evolutionary conservation of the
L73P, S151D, and D319Nmutation sites (Table 2) [24–26].The
homologymodel illustrates positions of these conserved sites
in zebrafish ERK2 molecule (Figure 1).
The mutations that were found to activate rERK2 were
introduced into pCS2+zERK1 and pCS2+zERK2 constructs
by site-directed mutagenesis. To determine whether single
mutation or a combination of two or three mutations would
increase zERK activity we constructed single, double, and
triple mutants of both zERK1 and zERK2. Altogether, six
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Figure 1: Overlap of homology predicted protein models showing
the active (grey) and inactive (white) zebrafish ERK2 protein struc-
ture. Phosphorylation of the dual phosphorylation site (TEY) causes
structural rearrangement of the activation lip.The substitutionsmay
cause rearrangements of intermolecular interactions between amino
acids resulting in a smaller distance between the activation lip with
the TEY motif and the catalytic site and facilitating autophospho-
rylation. The L83P site (blue) is located in 𝛼-helix C and S162D
(green) in the catalytic loop, both in the active site of the kinase.The
D330N (red) mutation is located in the CD-site which is a docking
site for inhibitory phosphatases. The D330N substitution prevents
ERK inhibitory phosphatases to bind. The atomic resolution mod-
els of zebrafish ERK2 were constructed with the zERK2 amino
acid sequence (ENSAMBLE:ENSDARP00000038550) and based
on three-dimensional X-ray crystallography predictions PDB:1ERK
and PDB:2ERK (phosphorylated). Homology modelling was per-
formed using free online Swiss model and models were illustrated
with Chimera.
potential constitutive active ERK mutants were obtained:
zERK1L106P, zERK 1L106P/S184D, zERK 1L106P/S184D/D352N,
zERK2L84P, zERK 2L84P/S162D, and zERK2L84P/S162D/D330N.
3.2. Erk2 Double and Triple Mutants Phosphorylate Down-
stream Targets In Vitro Despite Growth Factor Deprivation.
To compare the activity of ERK mutants and wild-type
(wt) proteins we performed a biochemical characterization
experiment after transfection of corresponding plasmids
into cultured zebrafish fibroblast (zf4) cells (Figure 2). The
transfected cells were starved for 6.5 h in cell culturemedium
without FCS before protein isolation. Since the MAPK/ERK
pathway is known to be induced by growth factors, we
expected the activity of endogenous and ectopic ERK to
be decreased to basal levels by starvation, enabling us to
compare downstream signalling betweenwt andmutant ERK
proteins. Subsequent western blottingwith antibodies against
total ERK showed that all transfected zebrafish ERK1 (data
not shown) and ERK2 constructs were expressed in zf4 cells
(Figure 2(a)). In addition to the band of endogenous zERK,
visible in all samples, a second band was detected in protein
samples of ERK1 and ERK2 transfected cells but not in the
control untransfected cells and the cells transfected with
PCS2+eGFP. The extra bands have the exact molecular mass
of the ectopic zERKs which are modified to have a 1.66 and
1.23 kD higher molecular mass than the endogenous zERK1
and zERK2, respectively. The bands of ectopic zERK1 (data
not shown) and zERK2 were also visible after detection with
antibody against phosphorylated ERK1/2 in samples of the
ERK transfected cells. To be able to detect differences in the
degree of target phosphorylation between mutant and wild-
type zERKs, antibodies against phosphorylated p90 riboso-
mal S6 kinase (p90RSK), cAMP response element-binding
protein (CREB) were used (Figures 2(b)–2(d)). Western
blotting quantification and subsequent correction for ectopic
ERK synthesis and normalization against wt ERK confirm the
increased phosphorylation of the triplemutants of both ERK1
and ERK2. For the detection of phosphorylated p90RSK, two
different antibodies were available, which cross reacted with
the zebrafish ortholog, directed against distinct sites targeted
by ERK.With both antibodies, an increased phosphorylation
of p90RSKwas found in cells transfected with the double and
triple mutants of zERK2 only when compared to cells with
wt ERK 1/2 overexpression. In addition, phosphorylation
increase of the other ERK target CREB was detected in the
zERK2 double and triple mutant samples. No increase of
either phosphorylated p90RSK or CREB was detected in
cells transfected with wild-type or mutated ERK1 (data not
shown).
3.3. CA-ERK2 and FGF8 Induce Transgene Expression
of Tg(Dusp6:d2EGFP). Synthesized ERK2 wt and mutant
mRNA were injected in 1-cell stage zebrafish embryos for
in vivo validation of constitutive activation. Ectopic phos-
phorylated ERK was detectable in protein samples collected
at 5 hpf with western blotting (Figure 3(a)). In addition, the
ERK2 triple mutant was significantly more phosphorylated
and the double mutant was slightly increased compared
to the ectopic wt ERK2 and the ERK2 single mutant.
Therefore, we continued the validation of the double and
triple ERK2 mutants in vivo, based on an ERK2 negative
feedback mechanism, involving the downstream gene target
dual specificity phosphatase (DUSP6) in Tg(Dusp6:d2EGFP)
(Figure 3(b)). The FGF8 morphogen induces ERK activity
at the dorsal site and the margin of the zebrafish embryo
during epiboly. Subsequently, ERK2 induces the expression of
DUSP6 which is a dual specificity phosphatase that removes
both activating phosphates of the ERK2 (Thr-Glu-Tyr) motif
[27].When FGF8mRNAwas injected in Tg(Dusp6:d2EGFP)
embryos, the GFP signal increased and shifts from the
dorsal site to the entire animal pole (Figure 3(b)). Batches
of Tg(Dusp6:d2EGFP) embryos were injected with wt ERK2,
ERK2 double mutant, triple mutant, and FGF8 mRNA and
analyzed with the COPAS XL which performs large-scale
GFP fluorescence detection of live embryos. Both mutants
as well as FGF8 increased the eGFP signal in heterozygous
Tg(Dusp6:d2EGFP) embryos at 5 hpf (Figure 3(c)).
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Figure 2: Western blot detection of ERK1/2, P90RSK, and CREB phosphorylation in zf4 cells transfected with PCS2+ERK1 and PCS2+ERK2
(mutated) constructs. (a)Western blotting was performedwith total ERK and dpERK.The Ectopic ERKs derived from synthetic mRNAs have
a greater MW than the endogenous ERKs, due to the introduction of a small linker, and can therefore be distinguished by size. The bands
with higher molecular mass were also detected with anti-ERK 1/2 antibody in cells transfected with ERKTEY mutants but not with the anti-
phospho-ERK 1/2 antibody. This confirms that the bands with higher molecular weights are from the transfected ectopic ERK. (b) Western
blot detection of phospho-p90Rsk with two different antibodies one targeted against Thr573 and another against Ser380. (c) Western blot
detectionwith the phospho-Creb Ser133 antibodywhich cross-reactswith phospho-ATF. (d) Band intensitiesweremeasured for quantification
of western blots ((a)–(c)) dp-ERK(ectopic) p-P90RSK and p-CREB band intensities were corrected for total ectopic ERK synthesis. Mutants
were normalized against ERK1-WT or ERK2-WT.WT: protein samples from zf4 cells transfected with wtERK 1 or wtERK 2, ∗: single mutants
ERK1L106PERK2L84P, ∗∗: double mutants ERK1L106P/S184DERK2L84P/D162D, ∗∗∗: triple mutants ERK1L106P/S184D/D352NERK2L84P/S162D/D330N, TEY:
ERK1T216A/Y218A, and ERK2T194A/Y196A 0: untransfected zf4 cells, EGFP: zf4 cells transfected with pcs2+EGFP.
3.4. Kinome Profiling Reveals Increased Phosphorylation of
the Cell Cycle Progression Protein CDK1 as a Consequence of
FGF8 and CA-ERK2 Overexpression in Zebrafish Embryos.
To identify substrates that are in particular affected by ERK
constitutive activation, we performed a serine threonine
phosphokinome peptide array experiment comparing lysates
of ERK2∗∗∗, ERKWT, and FGF8 injected embryos against
an uninjected control. 111 peptides were phosphorylated
by the zebrafish lysates and with model-based clustering
7 clusters were distinguished from this pool (Figure 4).
Cluster 1 comprises peptides which are less phosphory-
lated due to FGF8 overexpression, while cluster 2 is show-
ing the opposite effect of FGF8-specific targets which are
increasingly phosphorylated (Tables 3 and 5). Clusters 3
and 4 represent peptides with decreased and increased
phosphorylation, respectively, as a result of wt ERK2 over-
expression. This might be the effects of negative feedback
as a consequence of ERK overexpression that have less
or no effect on the mutant. Clusters 5 and 7 are less
phosphorylated peptides due to overactivation of the FGF-
ERK pathway or due to injection. Cluster 6 consists of
an interesting group of peptides which are increasingly
phosphorylated by both FGF8 and the ERK2∗∗∗ mutant
(Tables 4 and 6). The proliferation marker CDK1 (CDC2) is
found among the cluster 6 peptides of which phosphoryla-
tion within amino acids 154–169 is significantly induced by
FGF8 and ERK∗∗∗(P value < 0.05) compared to uninjected
embryos.
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Figure 3: In vivo ERK signaling activity analysis of ectopically expressed FGF or ERK isoforms.(a) western blot detection of dpERK on
protein samples isolations from 5 hpf embryos injectedwith 50 pgWTormutant ERK2mRNAand isolated. (b) Flowchart of the experimental
procedure using the Tg(Dusp6:d2EGFP) and subsequent COPAS XLUnion Biometrica.analysis (c). 5 hpf old living embryos are passed through the
COPAS flowcell and optical density/axial length (blue), GFP (green), YFP (yellow), and dsRED (red) fluorescence profiles are recorded Union
Biometrica, Inc. D. Peak height values (PH) of the GFP channel were collected for ERK2 WT, ERK2∗∗, ERK2∗∗∗, and FGF8 mRNA injected
embryos, after corrected for autofluorescence/background of noninjected wild-type embryos (see Section 2), and plotted in a bar graph as
the mean value of three biological experiments, each with a minimum of 30 embryos/condition. Mean GFP PH values are normalized against
ERK2 WT. Arrow bares represent standard deviations of the means of the three biological experiments; P values were calculated by applying
a t-test with Welch-correction.
4. Discussion
Three point mutations, which already were shown to acti-
vate rat ERK2, were sequentially introduced in zERK1 and
zERK2 providing us with six mutants to be tested for in-
creased activation [24]. The six mutants include the single
mutants zERK1L106P and zERK2L84P, the double mutants
zERK1L106P/S184D and zERK2L84P/S162D, and finally the triple
mutants zERK1L106P/S184D/D352N and zERK2L84P/S162D/D330N.
The Western blot results with total and dpERK antibodies
showed that all mutants were successfully expressed and
phosphorylated in zf4 cells. In addition, western blot analysis
ISRN Cell Biology 7
Table 3: Cluster 2 Peptides with increased phosphorylation specifically by FGF8 samples. Protein samples were prepared at 5 hpf. ANOVA
and Dunnett’s test are performed with a biological triplicate.
Peptide Fold change (mean 2log values) 𝑃 values versus WT 𝑃 values versus ERK2 WT
WT ERK2WT ERK2∗∗∗ FGF8 ERK2WT ERK2∗∗∗ FGF8 ERK2∗∗∗ FGF8
ACM5 494 506 1.00 0.99 1.02 1.04 0.909 0.925 0.093 0.835 0.079
ACM5 498 510 1.00 0.98 1.01 1.08 0.897 0.730 0.119 0.637 0.143
ANDR 785 797 1.00 0.98 1.01 1.05 0.923 0.471 0.153 0.529 0.133
CA2D1 494 506 1.00 1.05 1.06 1.10 0.290 0.364 0.012† 0.864 0.056
ESR1 160 172 1.00 0.97 0.99 1.04 0.451 0.189 0.183 0.523 0.060
GPR6 349 361 1.00 0.96 1.01 1.02 0.382 0.465 0.609 0.876 0.189
GSUB 61 73 1.00 0.98 0.93 1.05 0.441 0.147 0.942 0.432 0.402
KS6A1 374 386 1.00 1.00 1.02 1.09 0.969 0.822 0.430 0.852 0.409
P53 12 24 1.00 1.07 0.97 1.58 0.906 0.543 0.472 0.472 0.543
†
𝑃 values < 0.05.
Table 4: Cluster 6 peptides are increasingly phosphorylated by FGF8 or ERK2∗∗∗ but not ERK2WT samples. ANOVA and Dunnett’s test are
performed with a biological triplicate.
Peptide Fold change (from mean 2log) 𝑃 values versus WT 𝑃 values versus ERK2 WT
WT ERK2WT ERK2∗∗∗ FGF8 ERK2WT ERK2∗∗∗ FGF8 ERK2∗∗∗ FGF8
RBL2 655 667 1.00 0.93 1.11 1.31 0.772 0.671 0.205 0.482 0.135
PRKDC 2618 2630 1.00 0.98 1.17 1.63 0.734 0.618 0.267 0.412 0.165
PP2AB 297 309 1.00 0.88 1.11 1.27 0.270 0.307 0.510 0.058 0.104
MBP 222 234 1.00 0.94 1.19 1.05 0.697 0.055 0.591 0.032† 0.367
NEK3 158 170 1.00 1.21 1.27 1.50 0.516 0.093 0.031† 0.240 0.080
KCC2G 278 289 1.00 1.02 1.28 1.43 0.537 0.099 0.012† 0.040† 0.006†
CGHB 109 121 1.00 0.97 1.29 1.20 0.446 0.064 0.143 0.022† 0.047†
CDC2 154 169 1.00 0.95 1.11 1.15 0.982 0.041† 0.037† 0.042† 0.038†
†
𝑃 values < 0.05.
with dp-ERK after transfection of zf4 cells (Figure 2(a)) as
well as mRNA injection in zebrafish embryos (Figure 3(a))
clearly showed increased TEY phosphorylation of zERK1
(data not shown) and zERK2 triple mutants. Compared to
the wild type isoforms of the proteins showed that the ERK2
double mutant induced a slight increase in signaling to
downstream targets, despite the poorly detectable increase of
its TEY phosphorylation in transfected zf4 cells. This could
have been a detection discrepancy of this assay as the double
mutant appears to be indeed more phosphorylated at its
dual phosphorylation site in zebrafish embryos (Figure 3(a)).
Strikingly, the triple mutant of ERK2 revealed clear hyper-
phosphorylation of ERK substrates P90RSK and CREB (Fig-
ures 2(b)–2(d)). In the absence of growth factor stimula-
tion zERK2L84P/S162D and zERK2L84P/S162D/D330N maintained
activity and phosphorylation of substrates in zf4 cells. How-
ever after 6 hours of starvation phosphorylated endoge-
nous ERK1/2, the high-intensity bands (phospho-ERK1 and
phospho-ERK2 combined) on the blot (Figure 2(a)), was still
abundantly present in zf4 cells and the question remains
how the ectopic ERK2 mutants have caused this increase
of P90RSK and CREB phosphorylation. It is possible that
the mutations have influenced ERK2 signalling dynamics
through affecting its shuttling rate between cytoplasm and
nucleus. The cytoplasmic nuclear shuttling rate of ERK2
increased after treatment with fibroblast growth factor (FGF)
or epidermal growth factor [28, 29].
We continued investigating the constitutive active
ERK2 double and triple mutants in heterozygous
Tg(Dusp6:d2EGFP) at 5 hpf and included FGF8 as a positive
control. eGFP induction after FGF8 mRNA injection was
demonstrated previously by Molina et al. using fluorescent
microscopy [30]. We were able to quantify increased eGFP
fluorescence in batches of minimal 30 FGF8 mRNA injected
embryos with the COPAS XL (Figure 3). During zebrafish
epiboly FGF8 acts as a morphogen which induces the
MEK/ERK pathway at the margin where it regulates the gene
expression of DUSP6 [27]. Therefore, along with FGF8 we
injected the ERK2 WT, double, and triple mutants for in
vivo quantitative fluorescent detection and conclude that the
ERK2 double and triple mutants are more potent to induce
downstream gene expression than the WT form. For the
next experiment, we proceeded further with the ERK2 triple
mutant because the in vivomonitored increase in activity was
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Table 5: Cluster 2 gene ontology.
Peptide Name protein Functions
P53 12 24
Cellular tumor antigen p53. Tumor
suppressor p53. Phosphoprotein
p53. Antigen NY-CO-13
Protein import into nucleus, negative regulation of transcription from RNA
polymerase II promoter, transcription factor activity, embryonic development,
somitogenesis, release of cytochrome c from mitochondria, T cell
proliferation involved in immune response, B/T cell lineage commitment,
DNA binding chromatin binding, DNA double-strand break repair, apoptotic
process, DNA damage response, ER overload response, cell cycle arrest, Ras
protein signal transduction, multicellular organismal development,
gastrulation, negative regulation of neuroblast proliferation, central nervous
system development, cell aging, blood coagulation, rRNA transcription, X-ray
response, gamma radiation
KS6A1 374 386
Ribosomal protein S6 kinase
alpha-1.S6K-alpha 1. p90-RSK 1.
pp90RSK1. p90S6K. RSK-1.
MAPKAPK1A
Toll-like receptor signaling pathway, cell cycle, synaptic transmission, axon
guidance, negative regulation of apoptotic process, regulation of translation in
response to stress, regulation of DNA-dependent transcription in response to
stress, innate immune response, cell differentiation positive regulation of
transcription from RNA polymerase II promoter, nerve growth factor receptor
signaling pathway, stress-activated MAPK cascade
GSUB 61 73
G-substrate. C7orf16.protein
phosphatase 1. regulatory subunit 17
(PPP1R17)
Central nervous system development
GPR6 349 361 Sphingosine 1-phosphate receptor.G-protein coupled receptor 6 G-protein coupled receptor activity
ESR1 160 172
Estrogen receptor (ER). Estradiol
receptor (ER-alpha). Nuclear
receptor subfamily 3 group A
member 1
Epithelial cell development, osteoblast development, sequence-specific DNA
binding, transcription factor activity, steroid hormone receptor activity,
DNA-dependent transcription initiation from RNA polymerase II promoter,
beta-catenin binding, transcription factor binding, androgen metabolic
process, chromatin remodeling complex, nitric-oxide synthase regulator,
estrogen receptor signaling pathway, type 1 metabotropic glutamate receptor
binding, response to estradiol stimulus, regulation of apoptotic
CA2D1 494 506
Voltage-dependent calcium channel
subunit alpha-2/delta-1 precursor.
CACNA2D1
Voltage-gated calcium channel complex, sarcoplasmic reticulum, T-tubule
ANDR 785 797
Androgen receptor.
Dihydrotestosterone receptor.
Nuclear receptor subfamily 3 group
C member 4
In utero embryonic development, DNA binding, chromatin binding,
transcription factor activity, androgen receptor activity, sex differentiation,
beta-catenin binding, positive regulation of cell proliferation, male gonad
development, prostate gland development, response to insulin stimulus,
positive regulation of intracellular estrogen receptor signaling pathway,
negative regulation of apoptotic process, positive regulation of MAPK
cascade, positive regulation of insulin-like growth factor receptor signaling
pathway, positive regulation of integrin biosynthetic process, negative
regulation of epithelial cell proliferation, positive regulation of NF-kappaB
transcription factor activity, prostate gland development
ACM5 498 510
ACM5 494 506
Muscarinic acetylcholine receptor
M5. cholinergic receptor.
muscarinic 5
more significant than that of the double mutant. In addition
to the two substitutions that facilitate autophosphorylation,
the triple mutant contains an extra substitution in the
phosphatases interacting motif which prevents inactivation
of ERK2 by feedback signaling, resulting in the highest
phosphorylation activity level for the triple mutant isoform.
The fibroblast growth factors are known to bind to their
corresponding tyrosine kinase receptors and they relay the
extracellular signals further to the ERK/MAPK pathway and
the PI3/AKT pathway. Therefore, part of FGF downstream
signaling should overlap with ERK2 downstream signaling.
To identify this pool of substrates in zebrafish cell lysates
isolated from 5 hours old embryos, using PamGene serine
threonine kinome peptide arrays (Figure 4), kinome profiles
of embryos injected with FGF8, wt ERK2, and ERK2 triple
mutant mRNA were compared against uninjected wt with
model-based clustering. The 7 clusters of peptides were
identified of which cluster 6 represents the overlapping
pool of peptides induced by FGF8 and ERK2 triple mutant
and cluster 2 the FGF8 targets independent of ERK/MAPK
ISRN Cell Biology 9
Table 6: Cluster 6 gene ontology.
Peptide Name protein Functions
RBL2 655 667 Retinoblastoma-like protein2.p130.PRB2. RBR-2
Tumor suppressor, inhibitor of E2F-mediated transactivation, cell cycle
regulation and proliferation, differentiation during human placental
development
PRKDC 2618 2630
DNA-dependent protein kinase
catalytic subunit (DNA-PKcs).
DNPK1.p350
Apoptosis (FAS signaling pathway) Cell Cycle: G2/M Checkpoint, B-cell
differentiation, telomere maintenance, DNA double strand break repair,
transcription factor
PP2AB 297 309
Serine/threonine-protein
phosphatase 2A catalytic subunit
beta isoform. PP2A-beta.
PPP2CB. PPM1B
Fibroblast growth factor receptor signaling pathway, negative regulation of
Ras protein signal transduction, negative regulation of apoptotic process,
proteasomal ubiquitin-dependent protein catabolic process
MBP 222 234
Myelin basic protein. Myelin A1
protein. Myelin
membraneencephalitogenic
protein
Protease binding, immune response, synaptic transmission, structural
constituent of myelin sheath
NEK3 158 170 NimA-related protein kinase 3.HSPK 36 Protein serine/threonine kinase activity, cell cycle, mitosis, cell division
KCC2G 278 289
Calcium/calmodulin-dependent
protein kinase type II gamma
chain. CaM kinase II subunit
gamma, CaMK-II subunit
gamma. CAMK2G
G1/S transition of mitotic cell cycle, response to hypoxia, synaptic
transmission, cytokine-mediated signaling pathway, insulin secretion
CGHB 109 121
Choriogonadotropin subunit
beta precursor. CGB5. HCG.
CG-beta
Hormone-mediated signaling pathway
CDC2 154 169
Cell division control protein 2
homolog.p34 protein kinase.
Cyclin-dependent kinase 1.
CDK1. CDC28A. P34CDC2
Cell cycle checkpoint, G1/S transition of mitotic cell cycle, MAPK cascade
activation, microtubule cytoskeleton organization, toll-like receptor signaling
pathway, cyclin-dependent protein kinase activity, spindle microtubule, DNA
replication, DNA repair protein complex assembly, apoptotic process, DNA
damage checkpoint, epidermal growth factor receptor signaling pathway, Ras
protein signal transduction, pronuclear fusion, axon guidance, cell aging,
insulin receptor signaling pathway, RNA polymerase II carboxy-terminal
domain kinase activity, fibroblast growth factor receptor signaling pathway,
gene expression, regulation of Schwann cell
signaling. However, the fold induction of phosphorylation
of each peptide compared to the uninjected control was
quite low and often did not exceed the variation between the
biological triplicates and therefore we could not demonstrate
its significance using statistical tests. This is possibly due to
the endogenous ERK2 signaling already present in the cell
lysates. Despite this difficulty, we found phosphorylation on
the 154–162 amino acids of the peptide corresponding to the
cell proliferation marker CDK1 (CDC2), to be significantly
increased in embryo lysates overexpressing ERK2∗∗∗ and
FGF8. Direct interaction of active ERK2 with CDC2/CDK1
has not been demonstrated before, but both kinases are
key players in cell cycle regulation and known to promote
G2/M transition and proliferation. In response to mitotic
stimulation ERK2 is known to induce expression of cyclin
D, which binds and activates CDK4 and CDK6. In addition,
activated ERK2 increased the expression of cyclin A, which
binds to either CDK1 or CDK2 [31]. The cyclinA/B-CDK1
complex becomes fully functional after dephosphorylation of
inhibitory Tyr15 and Thr14 residues and phosphorylation of
Thr161 on CDK1 by Cdk Activating Kinases (CAK) [32, 33].
Themolecular mechanism connecting ERK2 and CAK, lead-
ing to increasedThr161 phosphorylation of CDK1, remains to
be identified.
5. Conclusion
In this study, we have successfully constructed two consti-
tutive active zebrafish ERK2 mutants zERK2L84P/S162D and
zERK2L84P/S162D/D330N which continue to drive downstream
signaling during growth factor deprivation in vitro andwhich
are more potent to relay signals to the nucleus and induce
target gene transcription in vivo. In addition, cell proliferation
can be induced by zERK2L84P/S162D/D330N as elevated ERK2
signals increase the phosphorylation of CDK1, a key protein
involved in promoting cell cycle progression. Future research
will be focusing on the possible long-term effect of consti-
tutive ERK2 activation by developing transgenic zebrafish
lines that drive constitutive active ERK2 isoforms under the
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FGF
ERK2
Cluster 2Cluster 6
1
2
3
4
5
6
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Cluster ERK2∗∗∗ ERK2WT FGF8 WT
AKT/PLC𝛾
Figure 4: Kinome profile clustering of embryos ectopically express-
ing ERK2WT, ERK2 triple mutant, and FGF8. Simplified repre-
sentation of FGF-ERK signalling pathways to downstream specific
target clusters (up). Clusters are based on a Bionavigator-based
clustering algorithm, which groups peptides into clusters according
to treatment-based response similarities (down). AKT is Protein
Kinase B (PKB), PLC𝛾 is Phospholipase C𝛾.
control of the melanocyte-specific promoters mitfa or kita.
Analysis of the specific downstream molecular mechanisms
that are involved in oncogenic transformationwill attribute to
the specific role ofMAPK signaling, when compared to other
systems such as the BRAF (BRAFV600E) transgenic fish line.
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